<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03018067</url>
  </required_header>
  <id_info>
    <org_study_id>RDX227675-201</org_study_id>
    <nct_id>NCT03018067</nct_id>
  </id_info>
  <brief_title>A Study Evaluating the Onset-of-Action, Safety, and Efficacy of RDX227675 for the Treatment of Hyperkalemia</brief_title>
  <official_title>A Single-Blind, Placebo-Controlled Study Evaluating the Onset-of-Action, Safety, and Efficacy of RDX227675 for the Treatment of Hyperkalemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ardelyx</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ardelyx</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase 2, single-blind, placebo-controlled study will evaluate the onset-of-action,
      safety, and efficacy of RDX227675 for the treatment of hyperkalemia. Subjects who qualify are
      randomized into one of four treatment groups: Group 1 (Placebo qd), Group 2 (RDX227675 10 g
      qd), Group 3 (RDX227675 20 g qd), Group 4 (RDX227675 30 g qd).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study consists of a screening visit, a 7-day treatment period, and a 7-day treatment-free
      follow-up period.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2017</start_date>
  <primary_completion_date type="Anticipated">May 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Exponential Rate of Change in Serum Potassium from Baseline</measure>
    <time_frame>48 hours</time_frame>
    <description>Onset of Action</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Serum Potassium Levels</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment - Emergent Adverse Events [Safety and Tolerability]</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Hyperkalemia</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Microcrystalline Cellulose (MCC), 2 g qd. Subjects assigned to the Placebo group will be randomly assigned in a 1:1:1 ratio to receive either one, two, or three bottles of drug per day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>10 g qd</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RDX227675, 10 g qd</description>
  </arm_group>
  <arm_group>
    <arm_group_label>20 g qd</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RDX227675, 20 g qd</description>
  </arm_group>
  <arm_group>
    <arm_group_label>30 g qd</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RDX227675, 30 g qd</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RDX227675</intervention_name>
    <arm_group_label>10 g qd</arm_group_label>
    <arm_group_label>20 g qd</arm_group_label>
    <arm_group_label>30 g qd</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 to 85 years old, inclusive

          -  Two consecutive i-STAT K values ≥ 5.5 to &lt; 6.5 mmol/L, measured a minimum of
             60-minutes apart within 1 day of first RDX227675 dose on Day 1 (prior to
             randomization)

          -  i-STAT K value ≥ 5.5 to &lt; 6.5 mmol/L on Day 1 (prior to randomization)

          -  Ability to have repeated blood draws or effective venous catheterization

          -  Females of child bearing potential must have negative urine pregnancy test on Day 1
             (prior to randomization)

          -  Females but be non-pregnant, non-lactating, and either be post-menopausal for at least
             12 months, have documentation of irreversible surgical sterilization, or confirm the
             use of one of the acceptable contraceptive methods

          -  Males must agree to use an appropriate method of contraception or have documented
             surgical sterilization

        Exclusion Criteria:

          -  Pseudohyperkalemia signs and symptoms

          -  Treatment with K lowering drugs, within 7 days prior to randomization

          -  Uncontrolled Type 2 diabetes, as defined as most recent historical HbA1c &gt; 10%, or
             hospitalization to treat hyper- or hypo-glycemia in the past 3 months

          -  Diabetic ketoacidosis

          -  Known hypersensitivity to polystyrene sulfonate

          -  Significant cardiovascular or cerebrovascular events in the past 2 months

          -  Severe heart failure, defined as NYHA (New York Heart Association) class IV or
             hospitalization to treat heart failure in previous 3 months

          -  History of bowel obstruction, swallowing disorders, severe gastrointestinal disorders,
             or major gastrointestinal surgery

          -  Major psychiatric disorder (DSM-III-R or DSM-IV) including major depression or other
             psychoses that has required hospitalization in the last 3 years. History of attempted
             suicide or uncontrolled bipolar disorder.

          -  Use of an investigational product within 30 days prior to Screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David P Rosenbaum, Ph.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Ardelyx, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>David P Rosenbaum, Ph.D.</last_name>
    <email>drosenbaum@ardelyx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Capital Nephrology Associates, PA</name>
      <address>
        <city>Cary</city>
        <state>North Carolina</state>
        <zip>27511</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 10, 2017</study_first_submitted>
  <study_first_submitted_qc>January 10, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 11, 2017</study_first_posted>
  <last_update_submitted>January 10, 2017</last_update_submitted>
  <last_update_submitted_qc>January 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperkalemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

